Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 21Prostatic Neoplasms 11Neoplasms 8Head and Neck Neoplasms 8Ovarian Neoplasms 6Oropharyngeal Neoplasms 4Lung Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Sarcoma 3Rectal Neoplasms 3Polycystic Ovary Syndrome 3Pancreatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Brain Neoplasms 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Psychological Well-Being 2Motor Activity 2Melanoma 2Kidney Neoplasms 2Hematologic Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Communication 2Colonic Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Rituximab 40Cyclophosphamide 36Prednisone 24Doxorubicin 23Magnetic Resonance Spectroscopy 20Vincristine 19Gemcitabine 18Specimen Handling 17Lenalidomide 17Biopsy 15Oxaliplatin 14polatuzumab vedotin 13obinutuzumab 11glofitamab 11ibrutinib 10fludarabine 8Etoposide 8Dexamethasone 8CT-P10 8prednylidene 7deltacortene 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6pembrolizumab 6Prednisolone 6fludarabine phosphate 5acalabrutinib 5R-CHOP protocol 5Cyclosporine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Surveys and Questionnaires × 90 days × Clear all
NCT07588698 2026-05-15

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡